Viable SARS-CoV-2 in various specimens from COVID-19 patients
Viable SARS-CoV-2 in various specimens from COVID-19 patients
复制标题
DOI：
10.1016/j.cmi.2020.07.020
复制
发表时间：
2020-11-01
影响因子：
14.2
通讯作者：
Choi, Young Ki
中科院分区：
文献类型：
--
作者：
Jeong, Hye Won;Kim, Se-Mi;Choi, Young Ki
目的：目的是确定从COVID-19患者获得的各种临床标本是否含有感染性病毒。方法：为了证明各种临床标本是否含有活病毒，我们收集了5名COVID-19患者的鼻/口咽拭子和唾液，尿液和粪便样本，并进行定量聚合酶链反应（qPCR）以评估病毒载量。对qPCR阳性标本在Vero细胞中进行病毒分离。我们还使用尿液和粪便样本，鼻内接种雪貂，并评估了病毒滴度在鼻洗液中的2，4，6和8天后infection.Results：SARS-CoV-2 RNA检测所有的鼻/口咽拭子和唾液，尿液和粪便样本之间收集的第8和30天的临床病程。值得注意的是，尿液、唾液和粪便样本中的病毒载量几乎等于或高于鼻/口咽拭子中的病毒载量（尿液1.08 +/- 0.16-2.09 +/- 0.85 log（10）拷贝/mL，唾液1.07 +/- 0.34-1.65 +/- 0.46 log（10）拷贝/mL，粪便1.17 +/- 0.32 log（10）拷贝/mL，鼻/口咽拭子1.18 +/- 0.12-1.34 +/- 0.30 log（10）拷贝/mL）。此外，从COVID-19患者的鼻/口咽拭子和唾液以及接种患者尿液或粪便的雪貂的鼻洗液中分离出了活的SARS-CoV-2。讨论：在COVID-19患者的唾液、尿液和粪便样本中证实了活的SARS-CoV-2，直至临床病程的第11-15天。这一结果表明，活的SARS-CoV-2可以在各种临床样本和呼吸道标本中分泌。(c)2020作者（S）由Elsevier Ltd代表欧洲临床微生物学和传染病学会出版。这是一个在CC BY-NC-ND许可证下的开放获取文章（http：//creativecommons.org/licenses/by-nc-nd/4.0/）。
Objectives: The aim was to determine whether various clinical specimens obtained from COVID-19 pa-tients contain the infectious virus.Methods: To demonstrate whether various clinical specimens contain the viable virus, we collected naso/ oropharyngeal swabs and saliva, urine and stool samples from five COVID-19 patients and performed a quantitative polymerase chain reaction (qPCR) to assess viral load. Specimens positive with qPCR were subjected to virus isolation in Vero cells. We also used urine and stool samples to intranasally inoculate ferrets and evaluated the virus titres in nasal washes on 2, 4, 6 and 8 days post infection.Results: SARS-CoV-2 RNA was detected in all naso/oropharyngeal swabs and saliva, urine and stool samples collected between days 8 and 30 of the clinical course. Notably, viral loads in urine, saliva and stool samples were almost equal to or higher than those in naso/oropharyngeal swabs (urine 1.08 +/- 0.16-2.09 +/- 0.85 log(10) copies/mL, saliva 1.07 +/- 0.34-1.65 +/- 0.46 log(10) copies/mL, stool 1.17 +/- 0.32 log(10) copies/mL, naso/oropharyngeal swabs 1.18 +/- 0.12-1.34 +/- 0.30 log(10) copies/mL). Further, viable SARSCoV-2 was isolated from naso/oropharyngeal swabs and saliva of COVID-19 patients, as well as nasal washes of ferrets inoculated with patient urine or stool.Discussion: Viable SARS-CoV-2 was demonstrated in saliva, urine and stool samples from COVID-19 patients up to days 11-15 of the clinical course. This result suggests that viable SARS-CoV-2 can be secreted in various clinical samples and respiratory specimens. (c) 2020 The Author(s). Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http:// creativecommons.org/licenses/by-nc-nd/4.0/).